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MicroRNAs (miRNAs) are involved in the regulation of many
cellular processes including hematopoiesis, with the aberrant
expression of differentiation-stage speciﬁc miRNA associated
with lymphomagenesis. miRNA proﬁling has been essential for
understanding the underlying biology of many hematological
malignancies; however the miRNA signature of the diverse
tumor clone associated with Waldenstrom’s macroglobuline-
mia (WM), consisting of B lymphocytes, plasmacytes and
lymphoplasmacytic cells, has not been characterized. We have
investigated the expression of over 13000 known and candidate
miRNAs in both CD19
þ and CD138
þ WM tumor cells, as well as
in their malignant and non-malignant counterparts. Although
neither CD19
þ nor CD138
þ WM cells were deﬁned by a distinct
miRNA proﬁle, the combination of all WM cells revealed a
unique miRNA transcriptome characterized by the dysregula-
tion of many miRNAs previously identiﬁed as crucial for normal
B-cell lineage differentiation. Speciﬁcally, miRNA-9*/152/182
were underexpressed in WM, whereas the expression
of miRNA-21/125b/181a/193b/223/363 were notably increased
(analysis of variance; Po0.0001). Future studies focusing on
the effects of these dysregulated miRNAs will provide further
insight into the mechanisms responsible for the pathogenesis
of WM.
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Introduction
Waldenstrom’s macroglobulinemia (WM) is a rare, non-Hodgkin’s
lymphoma, marked by a monoclonal immunoglobulin (Ig)M
gammopathy and tumor inﬁltration into the bone marrow and
lymphatic tissue.
1 Classiﬁed as a lymphoplasmacytic lymphoma,
the WM tumor clone comprised of B lineage cells across a
morphological continuum that includes B lymphocytes, plas-
macytoid cells and plasma cells, prompting many to postulate
that WM tumors arise during the differentiation of
B-lymphocytes into IgM-secreting plasma cells.
2 As a conse-
quence of this heterogeneity, it is not surprising that WM tumors
share biological characteristics and clinical manifestations
with other malignancies of B lineage cells such as chronic
lymphocytic leukemia (CLL) and multiple myeloma (MM). As
with CLL, WM tumors are indolent and proliferate slowly,
whereas the hypersecretion of Ig, also common to MM, is
responsible for much of the morbidity associated with WM. Yet,
unlike CLL and MM, the pathogenesis of WM has not been
commonly associated with the presence of cytogenetic or
epigenetic abnormalities, suggesting that other processes may
be regulating the behavior of WM tumor cells.
3–5
Comparing and contrasting the clonal compartments of WM
tumors with their lymphocytic and plasmacytic counterparts in
malignancies with more homogeneous tumor clones has begun
to enhance our understanding of the potential mechanisms
driving the development and maintenance of this disease.
Recently, gene expression proﬁles of B cells and plasma cells
from WM have been compared with B cells from CLL and
plasma cells from MM.
6,7 These analyses identiﬁed an mRNA
signature for WM tumor cells that displayed a higher degree
of similarity to CLL and non-malignant B cells than MM or
non-malignant plasma cells. Yet the level of mRNA expression
in the different WM samples included in the analyses was highly
dependent on the extent of tumor involvement of the bone
marrow, with the transcription proﬁle of cases demonstrating
low bone marrow inﬁltration clustering with normal plasma-
cytes. Because of this variability, the expression of only a small
set of genes uniquely characterized WM. Similarly, a recent
proteomics analysis identiﬁed the differential expression (4two-
fold difference in expression) of only 10 proteins in WM cells
as compared to non-malignant controls out of a total of 512
proteins assessed.
8 Taken together, these results suggest that
identifying unique factors responsible for the biological beha-
vior of WM tumors may be more challenging than in other
hematological malignancies.
MicroRNA (miRNA) are endogenous, short (19–22 nucleo-
tides), non-coding RNA molecules that act as negative regulators
of eukaryotic gene expression.
9 This regulation is accomplished
at the post-transcriptional level by the binding of miRNA to
30-untranslated regions of target transcripts.
10 Substantial
evidence exists, supporting the crucial role of miRNA in
controlling important biological processes, such as proliferation,
apoptosis, cellular signaling and metabolism.
11–13 Additionally,
the dynamic and temporal expression of lineage-speciﬁc
miRNAs during hematopoiesis is critical for the differentia-
tion of hematopoietic cells.
14,15 Ectopic expression of these
miRNAs, including miR-181a and -223, substantially altered
lineage commitment and differentiation and was associated
with lymphomagenesis in animal models, underscoring the
important regulatory role of miRNA in controlling normal
hematopoiesis.
14
The aberrant expression of miRNAs has been frequently
implicated in the development of malignancy, including
hematological disorders, leading to the classiﬁcation of many
miRNAs as oncogenes or oncomiRs.
16 The activation of
oncomiRs is often a direct result of genomic instability, with
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minimal regions of ampliﬁcation or on common breakpoints
associated with human cancers.
17 Additionally, many miRNAs
become dysregulated during the process of cellular transforma-
tion. Yet, the miRNA proﬁles of neoplastic cells often retain
inherited expression patterns reﬂective of their non-malignant
progenitors, including the expression of cell type-dependent and
differentiation stage-speciﬁc miRNAs.
18 Thus, the unique
miRNA signature of a tumor may provide clues as to both the
origin of the tumor itself, as well as the mechanisms controlling
tumorigenesis.
Recently, the miRNA expression proﬁle of WM B cells
was characterized. A distinct molecular signature, deﬁned by
the dysregulation of seven miRNAs, distinguished B cells of
patients diagnosed with WM from those of healthy subjects.
19
However, the morphology of WM tumors is heterogenous by
nature, consisting of plasmacytes and lymphoplasmacytic
cells, in addition to B lymphocytes. Thus, it is possible that
the differential expression of other miRNAs not previously
identiﬁed, speciﬁcally those involved in the regulation of Ig
production, may be detected in a more diverse WM tumor cell
population. Even more, comparisons between the miRNA
proﬁles of WM tumors and those of CLL and MM may reveal
differentially regulated miRNAs involved in abnormal differ-
entiation of B lineage cells. Identifying these miRNAs and their
potential gene targets will deepen our understanding of the
biological processes involved in WM pathogenesis.
Materials and methods
Patient specimens
Malignant B lineage cells were isolated from the bone marrow
and/or peripheral blood of patients diagnosed with WM, CLL or
MM. As a control, B lineage cells were also obtained from
13 healthy donors (non-malignant, NM). The collection of all
specimens was approved by the Mayo Foundation Institutional
Review Board, and informed patient consent was obtained
in accordance with the Declaration of Helsinki. The collected
samples were isolated using CD19- and/or CD138-positive
selection beads and a RoboSep Cell Separator per the
manufacturer’s instructions (Stem Cell Technologies;
Vancouver, BC, Canada). The groups were as follows: WM
19
þ138
þ (n¼8), WM 19
þ (n¼6), WM 138
þ (n¼3), NM
19
þ138
þ (n¼4), NM 19
þ (n¼3), NM 138
þ (n¼6), CLL 19
þ
(n¼5) and MM 138
þ (n¼5).
RNA isolation and microarray proﬁling
RNA was isolated from all specimens using the mirVANA RNA
Isolation kit (Ambion Inc., Austin, TX, USA) according to the
manufacturer’s protocol for total RNA isolation. Extracted RNA
was quantiﬁed using a Nanodrop ND-1000 spectrophotometer
(Nanodrop; Wilmington, DE, USA) and stored at  801C until
needed. Total RNA of 1mg from each sample was shipped to
Asuragen Services for miRNA proﬁling via their DiscovArray
miRNA Expression Service (Asuragen Services; Austin, TX,
USA). miRNA expression analysis was performed through the
hybridization of RNA to a custom-manufactured Affymetrix
Gene Chip (miRChip V1, Ambion Inc.) that targets 14215
orthologous candidate miRNAs including 452 conﬁrmed
human miRNAs derived from the Sanger miRBase version 9.2
(http://www.mirbase.org/). The 14215 miRNAs were measured
by two probes each (probes A and B for each miRNA).
The signal processing method utilized for the miRChip V1 array
involved multiple steps including probe speciﬁc signal detection
calls, corrections for background estimates and global normal-
ization across all signals detected. More speciﬁcally, a set of
G-C-matched anti-genomic oligonucleotides was employed as a
control for each probe. The signal derived from each probe
on an array was compared with the signal obtained from the
probe-speciﬁc anti-genomic control with a Wilcoxon rank-sum
test. According to Asuragen, a probe with detection Pp0.06 is
considered ‘detected above background.’ Probes with P-values
40.06 have insufﬁcient signal to discriminate from the back-
ground and were thus considered not detected Additionally, the
median signal arising from the oligonucleotide controls served
as an estimated background value and was subtracted from the
probe-speciﬁc signal to yield a normalized value used in
further analysis. Global normalization of all arrays within a
speciﬁc analysis experiment was achieved through the use of
the variance stabilization normalization method described by
Huber et al.
20 The post-normalized data is reported as general-
ized log2 (glog2).
Identiﬁcation of target genes
Putative miRNA binding sites were identiﬁed in the
30-untranslated regions of human target genes and their
orthologs, using the target prediction algorithms speciﬁc to
TargetScan v5.1 (http://www.targetscan.org/, Whitehead
Institute for Biomedical Research, Cambridge, MA, USA),
TarBase v5.c (http://diana.cslab.ece.ntua.gr/tarbase/, Alexander
Fleming Biomedical Sciences Research Center, Varkiza, Greece)
and miRanda (http://www.microrna.org/microrna/home.do,
Memorial Sloan-Kettering Cancer Center, New York, NY,
USA) web sites.
21–23 Speciﬁcally, genes with known association
to either Ig production or hematopoietic differentiation and also
possessing a high predicted efﬁcacy of binding score were
included for further discussion.
Statistical analysis
For statistical hypothesis testing, a two-sample t-test, with
assumption of equal variance was applied, and one-way
ANOVA was used for multiple group comparisons. If a probe
set was not detectable in any of the samples, the set was ﬁltered
out. Speciﬁc miRNA were considered to be signiﬁcantly
differentially expressed based on a cutoff P-value o0.001 and
an absolute fold-change in expression of greater than two
(absolute log2 difference 41).
Results
A total of 16 specimens were isolated from patients with a known
diagnosis of WM. At the time of diagnosis, all patients presented
with symptomatic disease. The median patient age was 74.5 years
(range 54–85) as compared with a median age of 72 years for
patients diagnosed with either CLL (n¼5, range 45–89 years) or
MM (n¼5, range 63–83 years). The median level of serum IgM in
WM patients was 1.65g/dl (range 0–6.4g/dl), with a median bone
marrow involvement of 60% (range 0–80%). Cytogenetic ﬁndings
were unremarkable for all patient samples, except for one
specimen with a reported 13q deletion.
Expression of 14125 putative and conﬁrmed miRNAs (28430
total probes) was initially assessed in malignant lymphoplasma-
cytic cells (CD19
þCD138
þ) derived from patients diagnosed
with WM. There were 4272 probes including all species with at
least one P-value p0.06, which were considered detectable
above background and included in the analyses. Comparisons
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from patients with CLL (CD19
þ), malignant plasma cells from
patients with MM (CD138
þ) and B-lineage cells from healthy
donors. Initial unsupervised hierarchical clustering, with aver-
age linkage method and Pearson’s correlation as the distance
metric, was performed all on ‘detectable’ probes. The heat map
generated from this analysis did not indicate a distinct cluster
corresponding to the double-sorted (CD19
þCD138
þ) WM cells
despite near perfect segregation of CLL and MM cells (Figure 1).
Instead, subsets of the CD19
þCD138
þ WM cells had patterns
of expression similar to CLL, whereas the signatures of other
CD19
þCD138
þ WM samples were more consistent with MM
or non-malignant cells.
The lack of a clear miRNA signature for lymphoplasmacytic
(CD19
þ138
þ) WM cells was not unexpected and is most likely
due to the tumor cell’s dual nature, possessing features of both
B lymphocytes and plasma cells. Therefore, separate analyses
for B cells (CD19
þ) and plasma cells (CD138
þ) derived from
WM tumors were performed and again compared with their
malignant and non-malignant counterparts. In the analysis for
B cells, the 531 probes that were different between any two
groups of CD19
þ WM, NM or CLL cells (group comparison
P-value p0.01) were used in the clustering analysis. As shown
in Figure 2, the majority of WM B lymphocyte samples clustered
distinctly on a separate dendrogram branch from both non-
malignant and CLL B-cell populations, but more closely
resembled the miRNA expression proﬁle of CLL cells. However,
two WM samples, both derived from patients with very low
percentages of bone marrow involvement, clustered with the
non-malignant B cells. With the removal of these two samples,
the miRNA signature of WM B cells was clearly deﬁned by a
number of consistently downregulated miRNAs as compared
with CLL and non-malignant B cells, including miR-151,
miR-335 and miR-342, whereas miRNA-373 was notably
increased in WM B cells (Po0.001, Figure 2). As with previous
reports, overall expression levels of miRNAs were higher in non-
malignant B cells as compared with malignant B cells, but a
small subset of miRNAs were routinely downregulated in
the non-malignant population, including miR-32, miR-142b,
miR-156, miR-215 and miR-338 (Po0.001).
24 Interestingly, the
most abundantly expressed miRNAs in CD19
þ B cells remained
largely constant regardless of pathology, with miR-15, miR-26a
and miR-150 being the three most highly expressed miRNA in
WM B cells, CLL B cells and normal B cells, respectively.
Conversely, miR-155 was expressed highly in CD19
þ CLL cells
as has been reported previously, but was not as abundant in
either non-malignant or WM B cells (Table 1).
25
Similarly, microarray analysis yielded individual signatures
for MM plasma cells and non-malignant plasma cells as well
(Figure 3). There were 937 probes that were different (P-value
p0.01) in at least one of the pair-wise group comparisons
between CD138
þ WM, NM and MM cells, and these 937
probes were used in the clustering analysis. Again, the majority
of CD138
þ WM cells clustered with MM plasma cells, yet
retained a distinct miRNA proﬁle of their own, characterized by
the increased expression of more than 40 candidate miRNAs
(Figure 2b). One CD138
þ WM sample was deﬁned by an
miRNA signature more similar to that of the non-malignant
plasma cells, which in general, was characterized by higher
levels of miRNA expression as compared with the malignant
plasma cells. This particular WM sample was found to have a
lower percentage of cellular involvement of the bone marrow
as compared with the other two cases in the WM 138
þ set. No
differentially expressed miRNA were detected when CD138
þ
WM cells were compared with CD19
þ WM cells. However, a
unique set of 48 miRNA discriminated between non-malignant
plasma cells and B cells, of which 43 were downregulated in
plasma cells. The ﬁve miRNA identiﬁed as being more
highy expressed in non-malignant plasma cells included
miR-152 (7.2-fold, Po0.0001), miR-148a (12.8-fold,
Po0.0001), miR-182 (13.45-fold, P¼0.0006), miR-193b
(18.1-fold, Po0.0001) and miR-96 (24.3-fold, Po0.0001).
Lastly, to account for the heterogeneity in the WM tumor
clone, all WM samples (B lymphocytes, plasma cells and
lymphoplasmacytic cells, n¼17) were analyzed collectively,
and the miRNA proﬁle obtained was compared with that of all
non-malignant B lineage cells (n¼8), as well as CLL B cells and
MM plasma cells. This analysis identiﬁed six miRNAs with
signiﬁcantly altered expression between WM cells and the
non-malignant group. Between these two cell populations,
miR-152 (10.7-fold, Po0.0001), miR-182 (12.1-fold,
Po0.0001), miR-373* (3.9-fold, P¼0.0007) and miR-575
(2.2-fold, P¼0.0003) were observed to be expressed at a higher
Figure 1 Proﬁling of miRNA expression in WM (CD19
þCD138
þ),
CLL (CD19
þ), MM (CD138
þ) and non-malignant B lineage cells
(CD19
þCD138
þ). Unsupervised hierarchical clustering was per-
formed using all miRs detected in at least one sample. Both candidate
miRNAs and known human miRNAs derived from the Sanger miRBase
have been included for analysis. Generalized log ratios (glog2) for
each miRNA are represented. Gradations of blue and red mean lower
and higher expression levels, respectively. WM indicates Walden-
strom’s macroglobulinemia; CLL, chronic lymphocytic leukemia;
MM, multiple myeloma; NM, non-malignant.
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pattern for miR-21 (4.4-fold, P¼0.0002) and miR-142-3p
(7.1-fold, P¼0.0007) (Figure 4). When compared with CLL
B lymphocytes, miR-125b (99.7-fold, P¼0.0003), miR-126
(68.5-fold, P¼0.0001), miR-181 (78.8-fold, P¼0.0003),
miR-193b (21.8-fold, P¼0.0003) and miR-451 (150.1-fold,
Po0.0001), demonstrated signiﬁcantly higher expression in
WM cells (Figures 4 and 5a). A set of eight miRNAs were
Figure 2 miRNA expression proﬁling in CD19
þ B cells and derived from WM, CLL and NM donors. Heatmaps were generated using
unsupervised hierarchical clustering of all miRs detected in at least one sample. Only known human miRNAs from the Sanger miRBase have been
included for analysis. Generalized log ratios (glog2) for each miRNA are represented. Gradations of blue and red mean lower and higher expression
levels, respectively.
Table 1 Ten most abundantly expressed miRNAs in WM (CD19
+, CD138
+ and CD19
+CD138
+), CLL (CD19
+), MM (CD138
+) and NM
B lymphocytes and plasma cells
19
+ NM 138
+ NM 19
+138
+ NM 19
+ WM 138
+ WM 19+138
+ WM 19
+ CLL 138
+ MM
150 638 638 15 15 150 150 148a
15 148a 150 150 638 15 26a 29a
26a 223 15 26a 223 26a 15 15
638 26a 223 638 150 29a 29a 26a
let-7f2 29a 26a 21 26 let-7f2 let-7g 29b
let-7g 15 148 223 29a 223 21 let-7f2
let-7a3 150 29a let-7g 23a let-7g let-7f2 638
29a let-7g let-7f2 let-7f2 21 21 29b let-7g
17 29b let7g let-7a let-7g 29b 155 29c
181a let-7f2 let-7a3 29a let7f2 let-7a3 let-7a3 150
Abbreviations: CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NM, non-malignant; WM, Waldenstrom’s macroglobulinemia.
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MM cells, with multiple probes identifying the upregulation
of miR-92 and miR-92b in WM cells (Figures 4 and 5b). After
differentially expressed miRNAs had been identiﬁed in WM,
predicted gene targets for each deregulated miRNA were
determined. Putative mRNA targets were selected based on a
high sequence complementarity and binding efﬁcacy between
the target gene and the deregulated miRNA, as well as a known
relevance to either Ig production and/or B lineage differentia-
tion. Selected targets are presented in Table 2.
Discussion
The tumor clone of WM is unique in its morphologic diversity,
consisting of B lymphocytes and plasmacytes, as well as
lymphoplasmacytoid cells. Phenotypically, WM cells maintain
characteristics of both B lymphocytes and plasmacytes, con-
sistent with the hypothesis that the WM tumor clone arises from
a mature, memory-like B-cell that has, through some degree of
differentiation, acquired the ability to secrete IgM.
26 Thus, clues
to understanding the mechanisms driving WM biology may lie
within this lymphoplasmacytic differentiation process itself.
Normal hematopoietic differentiation is tightly regulated by
both extrinsic signals derived from the cellular microenviron-
ment as well as intrinsic modulators, including miRNA.
Recently, distinctive miRNA expression signatures have been
deﬁned for speciﬁc stages of B-cell development. Forced
expression of differentiation stage-speciﬁc miRNAs in healthy
B cells has been associated with a multitude of outcomes
including the inhibition of B-cell maturation, premature plasma
differentiation and lymphomagenesis.
14,27–29 Initial miRNA
proﬁling in WM B cells identiﬁed a small set of dysregulated
miRNAs, many of which have been implicated in the normal
progression of germinal center B cells to mature plasma
cells.
19,30 To elaborate upon these ﬁndings, we proﬁled miRNA
expression in WM B cells and plasma cells, prototypic
malignant B cells and plasma cells derived from patients
with CLL and MM, respectively, and in their non-malignant
counterparts.
Unlike previous analyses, our study revealed a unique
signature for neither CD19
þ WM cells nor CD138
þ MM.
Some samples clustered more closely with non-malignant
B cells or plasma cells, whereas others more closely resembled
CLL or MM cells, each of which, as previously reported,
clustered as a homogenous group.
31,32 Although we acknowl-
edge that this variability may be largely due to the relatively
small sample sizes of our respective groups, our ﬁndings are also
consistent with earlier mRNA proﬁling studies, whereby the
variability in expression pattern was directly related to the extent
of WM disease in the patients from which the samples were
derived. Namely, the expression proﬁles of samples obtained
from patients with higher bone marrow involvement were more
similar to their malignant counterparts, whereas patients with
less involvement had samples that tended to cluster with the
respective non-malignant cells.
6,7 In our CD19
þ B-cell analysis,
the two WM samples with miRNA proﬁles bearing a stronger
resemblance to normal as opposed to malignant B cells were
Figure 3 miRNA expression proﬁling in CD138
þ plasma cells derived from WM, MM and NM donors. Heatmaps were generated using
unsupervised hierarchical clustering of all miRs detected in at least one sample. Only known human miRNAs from the Sanger miRBase have been
included for analysis. Generalized log ratios (glog2) for each miRNA are represented. Gradations of blue and red mean lower and higher expression
levels, respectively.
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lower levels of bone marrow involvement, suggesting that a
patient’s miRNA signature may change in response to treatment.
Similar post-treatment alterations in miRNA expression have
been demonstrated in vitro in BCWM.1 cells after exposure to
perifosine, bortezomib and rituximab.
19 Although the current
study was not designed to examine the effect of treatment on
miRNA expression, these initial cases suggest that patients who
respond to therapy with a reduction in bone marrow inﬁltration
may display an miRNA proﬁle more similar to non-malignant
cells, as compared with either non-responders or untreated
patients. However, this is merely speculative and must be
conﬁrmed in a larger study.
Despite the interpatient variability and lack of a distinct
miRNA transcriptome, dysregulation of miRNAs was still
observed in WM, even after combining CD19
þ, CD138
þ and
CD19
þCD138
þ cells together as one group in an attempt to
mimic the heterogeneity observed in WM tumors. Six miRNAs
were differentially expressed in WM as compared with non-
malignant B lineage cells, many of which have been mentioned
previously for their involvement in hematopoiesis and lympho-
magenesis, including miR-182, miR-21 and miR-142-3p.
28,33,34
The downregulation of miR-152, which demonstrated 10.7-fold
lower expression in WM, has been reported in other lympho-
cytic malignancies as well, often as a result of epigenetic
silencing.
35,36 One potential gene target of miR-152 based on
sequence complementarity is the Janus kinase family member,
Jak1, whose corresponding protein product is highly involved in
cytokine-mediated signaling.
37 Intriguingly, Jak1 was one of the
few proteins identiﬁed in a recent proteomics analysis as being
overexpressed in WM.
8 As Jak family proteins are frequently
implicated in the development of hematological malignancies, it
may be of interest in future studies to examine the relationship
between the downregulation of miR-152 and the upregulation of
Jak1 in WM.
In addition to non-malignant B lineage cells, the miRNA
expression proﬁle of the WM tumor clone was also compared
with the proﬁles of CLL and MM cells. Both miR-125b and
miR-181a were expressed at signiﬁcantly higher levels in WM
than in CLL (Table 2).
38 During normal hematopoiesis, the
expression of both of these miRNAs is much higher in germinal
center lymphocytes than in memory B cells or plasma cells, and
both miRNAs appear to be involved in preventing premature
plasmacytic differentiation through the repression of speciﬁc
transcription factors.
18,27,39 Namely, functional studies have
validated the binding of both miR-125b and miR-181a to the
30-untranslated regions of PDRM1 and IRF4, with other
predicted gene targets including IL6R, PAX5 and DUSP5
(Table 2).
18,27 Coexpression of PDRM1, which encodes for the
protein B lymphocyte-induced maturation protein-1 (BLIMP-1)
and IRF4 is essential for the post-GC differentiation of B cells
into Ig-secreting plasma cells.
40 Increases in BLIMP-1 and IRF4
produce reciprocal decreases in the expression of Bcl-6, which,
in serving as a crucial regulator of the GC reaction, must be
repressed for differentiation towards memory B cells and plasma
cells to occur.
41 Forced expression of miR-181a in activated
primary B cells prevented the induction of PDRM1 and IRF4 and
ultimately increased Bcl-6, which, in compromising plasmacytic
differentiation, produced a substantial increase in CD19
þ B
cells and a decrease in the survival of cultured myeloma
cells.
14,18,27 Similarly, when introduced into a cultured B-cell
line, miR-125b expression was associated with a decrease in
IgM secretion of more than 70%, whereas having no effect on B-
cell viability.
27
Yet, consistent with previous reports, our analysis also
detected the downregulation of miRNA-9* in WM cells as
compared with CD138
þ MM cells.
19,30 Curiously, miRNA-9* is
also a validated repressor of PDRM1 expression,
42 and down-
regulation of miRNA-9* would appear to counteract the effects
of increased miR-125b and miR-181a. However, evidence
suggests that disease states, such as lymphoma, are unlikely to
be driven entirely by one dysregulated miRNA and that instead,
it is subtle changes in the expression of multiple miRNAs with
overlapping targets that control pathogenesis.
43 Under this
Figure 4 Differentially expressed miRNAs in WM. All samples
derived from patients with WM (CD19
þ, CD138
þ, CD19
þCD138
þ)
were combined into one group (n¼17) for analysis and compared
with miRNA expression in (a) CD19
þ CLL, (b) CD138
þ MM and (c)
NM (CD19
þ, CD138
þ, CD19
þCD138) cells. Values are fold-change
in expression relative to CLL, MM or NM cells, respectively. Speciﬁc
miRNA were considered to be signiﬁcantly differentially expressed
based on a cutoff P-value o0.001 and an absolute fold-change in
expression of greater than two. Only known human miRNAs derived
from the Sanger miRBase were considered for analysis.
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expression of miR-181a and miR-125b in WM was not sufﬁcient
to counterbalance the effects of downregulated miRNA-9*, a
tumor cell might develop with the ability to hypersecrete
IgM while maintaining a B-cell phenotype. With potentially
hundreds of biologically active miRNAs interacting in this
manner within neoplastic cells, it becomes difﬁcult to elucidate
the effects of a single, isolated, dysregulated miRNA on a
disease state without fully appreciating the role of the miRNA
within the entire transcriptome.
Another challenge in studying miRNA activity in WM is that
unlike with other malignancies, we were not able to associate
any of the dysregulated miRNAs in WM cells with previously
described cytogenetic abnormalities identiﬁed in WM
tumors.
44,45 Furthermore, all but one WM patient sample
included in this analysis maintained a normal cytogenetic
proﬁle and the miRNA signature of the one patient with a
reported 13q deletion was not signiﬁcantly different than the
other samples. This suggests that the dysregulation of miRNAs in
WM may have a stronger extrinsic component, whereby soluble
factors within the microenvironment regulate the expression of
intratumoral miRNAs. Recent studies have deﬁned a mechanism
for cytokine-induced upregulation of mioRNAs occurring
through activation of the Jak/Stat signaling pathway.
46–48
Expression of these miRNAs, which include miR-let7a and
miR-21, is linked to increased cell survival and is further
potentiated through their own ability to heighten Stat phos-
phorylation by inducing downstream transcription factors. In
myeloma cells, two Stat3 binding sites were detected on the
upstream enhancer of miR-21. Addition of exogenous IL-6 led to
Figure 5 miRNA expression proﬁling in B lymphocytes and plasmacytes from WM tumors (CD19
þ, CD138
þ, CD19
þCD138
þ) and (a) CD19
þ
B lymphocytes from CLL and (b) CD138
þ plasmacytes from MM. Heatmaps were generated using unsupervised hierarchical clustering of all
differentially expressed miRNAs (Po0.001). Both human and orthologous miRNAs are included. Generalized log ratios (glog2) for each miRNA are
represented. Gradations of blue and red mean lower and higher expression levels, respectively.
Table 2 Dysregulated miRNAs in WM with putative mRNA targets involved in immunoglobulin secretion and/or B-cell differentiation
miRNA Chromosomal
location
Expression level Putative mRNA targets
a Role in lymphoma
9* 1q22 Low vs MM XBP1, BCL6, PRDM1, SOCS4,
SOCS5, JAK2
WM,
19,30 HL,
42 BL,
50 B-cell
differentiation
51
21 17q23.1 High vs NM IL12A, TIMP3, PTEN, IL12A NHL,
52 BCL,
28 NK,
53 WM
30
125b 21q21.1 High vs CLL IRF4, PRDM1, IL6R, CCR5 B-cell differentiation
18,27,29
152 17q21.32 Low vs MM, NM PTEN, SOCS3, STAT1, JAK1, IL15 SzS,
36 ALL
35
181a 1q32.1 High vs CLL TIMP3, DUSP5, BCL2, PRDM1,
BCL6, IL2, STAT3, PAX5, IRF4
NHL,
38 B-cell differentiation,
14
MDS,
54T-cell maturation
55
182 7q32.2 Low vs MM, NM IL2, PRDM1 HL,
34 MCL,
56 expansion of T-helper
cells
57
193b 16p13.12 High vs CLL
Low vs MM
SOCS3, IL17R, SOCS6 MM,
58 HSC
29
223 Xq12 High vs MM LMO2, STAT1, PRDM1, IL17R,
MYBL1, IRF4
B-cell differentiation,
14,15,18,51 CLL,
59
WM,
30 DLBCL
60
363 Xq26.2 High vs MM TACI, LMO2, BCL6, DUSP5, CIITA WM
19
Abbreviations: WM, Waldenstrom’s macroglobulinemia; HL, Hodgkin’s lymphoma; BL, Burkitts lymphoma; NHL, non-Hodgkin’s lymphoma;
BCL, B-cell lymphoma; NK, natural killer cell lymphoma; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndromes; MCL, mantle cell
lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; HSC, hematopoietic stem cells; DLBCL, diffuse large B-cell lymphoma.
aPredicted target genes identiﬁed from the TargetScan, TarBase and MirRanda databases.
Experimentally validated target genes are in bold.
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subsequent reduction in apoptosis.
46 In WM, IL-6 and its soluble
receptor have been identiﬁed as two of the most highly
expressed genes, and serum levels of IL-6 are signiﬁcantly
higher in patients with WM than in healthy controls.
6,49
Interestingly, our analysis has conﬁrmed the ﬁndings of Hunter
et al.
30 by also detecting signiﬁcantly higher levels of miR-21 in
WM cells as compared to non-malignant controls (Figure 3).
This evidence may indicate the presence of an autocrine or
paracrine mechanism by which high concentrations of IL-6 in
the WM tumor microenvironment are responsible for the
dysregulation of miR-21. However, the origins and ultimate
effects of elevated miR-21 expression on WM tumor biology
remain to be examined.
In conclusion, our genome-wide analysis has identiﬁed a
unique set of differentially expressed miRNA in a heterogeneous
sample of WM cells. Consistent with the results of earlier
miRNA-proﬁling studies in WM B cells, many of the dysregu-
lated miRNA in WM are also critical for normal hematopoiesis,
suggesting that subtle changes in the expression of these
regulatory miRNA may be sufﬁcient to drive lymphomagenesis.
Additionally, as the target genes for many of these miRNAs
overlap, it seems unlikely that single miRNAs predict the
behavior of a WM tumor, but instead, it is the intricate balance
that exists between these miRNAs that controls the fate of a B
lymphocyte. Future investigations into the effects of these
dysregulated miRNAs, both individually and in combination,
will provide further insight into the mechanisms responsible for
the pathogenesis of WM.
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